MiR-346 and TRAb as Predicative Factors for Relapse in Graves’ Disease Within One Year
暂无分享,去创建一个
[1] Hiroya Yamada,et al. Circulating MicroRNAs in Graves' Disease in Relation to Clinical Activity. , 2016, Thyroid : official journal of the American Thyroid Association.
[2] K. Badenhoop,et al. Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers , 2016, Reviews in Endocrine and Metabolic Disorders.
[3] J. Seckl,et al. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse. , 2016, Thyroid : official journal of the American Thyroid Association.
[4] J. Romaldini,et al. Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment. , 2015, Thyroid : official journal of the American Thyroid Association.
[5] B. Shi,et al. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment. , 2015, Annales d'endocrinologie.
[6] Huaxi Xu,et al. MiR-346 regulates CD4+CXCR5+ T cells in the pathogenesis of Graves’ disease , 2015, Endocrine.
[7] J. Hennessey,et al. A 2013 survey of clinical practice patterns in the management of primary hypothyroidism. , 2014, The Journal of clinical endocrinology and metabolism.
[8] M. Ostapczuk,et al. MicroRNAs miR-146a1, miR-155_2, and miR-200a1 are regulated in autoimmune thyroid diseases. , 2012, Thyroid : official journal of the American Thyroid Association.
[9] S. Juo,et al. Genotype and Phenotype Predictors of Relapse of Graves’ Disease after Antithyroid Drug Withdrawal , 2012, European Thyroid Journal.
[10] Huaxi Xu,et al. Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. , 2012, The Journal of clinical endocrinology and metabolism.
[11] Rosalind S. Brown,et al. Autoimmune Thyroid Disorders , 2011, Journal of thyroid research.
[12] Ryan M. O’Connell,et al. Physiological and pathological roles for microRNAs in the immune system , 2010, Nature Reviews Immunology.
[13] G. Brent. Graves’ Disease , 2000, Endocrine Updates.
[14] N. Morgenthaler,et al. Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission , 2007, Clinical endocrinology.
[15] M. Castellano,et al. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. , 2007, Endocrine journal.
[16] T. E. Hinds. Diseases , 2021, Modeling Biological Systems.
[17] B. Goichot,et al. Antithyroid drugs , 2005, The New England journal of medicine.
[18] U. Roggenbuck,et al. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. , 2002, Thyroid.
[19] B. Nygaard,et al. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease. , 2002, European journal of endocrinology.
[20] J. Franklyn,et al. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. , 2000, The Journal of clinical endocrinology and metabolism.
[21] A. Pinchera,et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. , 1997, Thyroid : official journal of the American Thyroid Association.
[22] J. Romaldini. Case selection and restrictions recommended to patients with hyperthyroidism in South America. , 1997, Thyroid : official journal of the American Thyroid Association.
[23] A. Weetman,et al. Autoimmune thyroid disease: further developments in our understanding. , 1994, Endocrine reviews.